Literature DB >> 6436379

Suppressed antibody responses to sheep erythrocytes in mice with chronic Trypanosoma cruzi infections are restored with interleukin 2.

S G Reed, J A Inverso, S B Roters.   

Abstract

Plaque-forming cell (PFC) responses to sheep erythrocytes (SRBC) in cultures of spleen cells from mice with chronic Trypanosoma cruzi infections were found to be suppressed. Responses were restored with purified interleukin 2 (IL 2) and with supernatants that contained IL 2. Interleukin 1 (IL 1) prepared from the P338D1 hybridoma had no effect on in vitro responses when added alone, nor did it augment the effects of IL 2-rich supernatant. Interleukin X (IL X) generated from the FS7-20.6.18 T cell hybridoma was not effective alone or in combination with IL 1, nor were significant additive effects seen when IL X was combined with IL 2. The restorative effect of the IL 2-containing FS6-14.13 hybridoma supernatant (FS6-SN) was concentration dependent and was not seen when supernatant was added after day 1 of the culture period. Thus IL 2 alone, but not IL 1 or IL X, was able to reconstitute spleen cell responses of infected mice. In vivo anti-SRBC responses were also restored when mice were treated with IL 2-rich supernatant after immunization with SRBC. The immunologic defect in the production of PFC to heterologous erythrocytes by mice with chronic T. cruzi infections has been identified as a lack of functional help normally provided by the T cell product IL 2.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6436379

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Repeated antigenic stimulation overcomes immunosuppression in experimental Chagas' disease.

Authors:  L Choromanski; R E Kuhn
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

2.  Trypanosoma cruzi-induced suppression of human peripheral blood lymphocytes activated via the alternative (CD2) pathway.

Authors:  L A Beltz; F Kierszenbaum; M B Sztein
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

3.  Effect of antigen-specific T helper cells or interleukin-2 on suppressive ability of macrophage subsets detected in spleens of Trypanosoma cruzi-infected mice as determined by limiting dilution-partition analysis.

Authors:  M C Cerrone; D M Ritter; R E Kuhn
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

4.  Depressed T-cell proliferation associated with susceptibility to experimental Taenia crassiceps infection.

Authors:  E Sciutto; G Fragoso; M Baca; V De la Cruz; L Lemus; E Lamoyi
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

5.  Regulation of Trypanosoma cruzi infection in mice by gamma interferon and interleukin 10: role of NK cells.

Authors:  F Cardillo; J C Voltarelli; S G Reed; J S Silva
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

6.  Impairment of monocytic function during Trypanosoma cruzi infection.

Authors:  M J Louie; W R Cuna; C Rodriguez De Cuna; L Mayer; K Sperber
Journal:  Clin Diagn Lab Immunol       Date:  1994-11

7.  Does interleukin-2 restore lymphocyte responses suppressed by Trypanosoma cruzi?

Authors:  F Kierszenbaum; H Mejia Lopez; M B Sztein
Journal:  Immunology       Date:  1993-11       Impact factor: 7.397

8.  Suppressive and augmentative effects of recombinant human interleukin-2 upon delayed type of hypersensitivity in the mouse.

Authors:  M Harada; K Mori; H Nishimoto
Journal:  Inflammation       Date:  1986-06       Impact factor: 4.092

9.  Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis.

Authors:  E M Carvalho; R Badaró; S G Reed; T C Jones; W D Johnson
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

10.  Interleukin 2 enhances specific and nonspecific immune responses in experimental Chagas' disease.

Authors:  L Choromanski; R E Kuhn
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.